All data are based on the daily closing price as of August 28, 2025
h

Hanmi Pharm. Co.

128940.KO
218.97 USD
4.24
+1.97%

Overview

Last close
218.97 usd
Market cap
2.78B usd
52 week high
258.79 usd
52 week low
146.58 usd
Target price
262.32 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
2.6383
Price/Book Value
3.3707
Enterprise Value
2.93B usd
EV/Revenue
2.767
EV/EBITDA
15.3897

Key financials

Revenue TTM
1.06B usd
Gross Profit TTM
578.79M usd
EBITDA TTM
210.92M usd
Earnings per Share
N/A usd
Dividend
0.9 usd
Total assets
1.45B usd
Net debt
N/A usd

About

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
  • Symbol
    128940.KO
  • Exchange
    KO
  • Isin
    KR7128940004
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Jae-Hyun Park
  • Headquarter
    Hwaseong-si
  • Web site
    https://www.hanmipharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top